Diseases such as lung cancer and the intermittent hypoxaemia or sleep fragmentation caused by OSA can influence the cardiovascular system, either by spreading or by secreting biological mediators or implementing mechanisms that have been proven to cause vascular damage. Finally, although the therapies used for the management of respiratory diseases are generally effective and safe, it is well known that many of the adverse effects of drugs, used in the management of pulmonary diseases, such as bronchodilators, corticosteroids, antibiotics, antifibrotics, anticoagulants, anti-tumoral and anti-inflammatory therapies, may incorporate a degree of cardiovascular risk, particularly in some particularly susceptible patients. In this ERS Monograph, we have tried to offer the reader a complete overview of the interaction between pulmonary diseases and CVDs, not only from an epidemiological point of view [1], but also from a pathophysiological [2], and more particularly, clinical and therapeutic point of view. Accordingly, after reviewing some basic concepts, the book has been divided into: firstly, each important group of respiratory diseases and their cardiopulmonary implications [3–14] then to the groups of drugs most used in pulmonology and their potential cardiovascular effects [15–19] and finally, to future diagnostic challenges in this field [20]. Three clinical cases have also been chosen to illustrate different situations taken from real life, in order to delve more fully into the concepts discussed in this book [21–23]. We hope that this Monograph provides you with some of the answers to the questions you have asked in daily practise when trying to diagnose and treat complex patients who suffer from both cardiovascular and respiratory pathology. That was our main objective. References 1. Soriano JB, Elosua R. Epidemiological aspects of cardiovascular and respiratory diseases. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 1–11. 2. Viglino D, Maltais F, Tamisier R. Common pathophysiological pathways of the autonomic nervous system. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 12–30. 3. Rogliani P, Calzetta L. Cardiovascular disease in COPD. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 47–65. 4. Ora J, Cavalli F, Cazzola M. Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 66–81. 5. Argueta FA, Alviar CL, Peters JI, et al. Chronic asthma and the risk of cardiovascular disease. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 82–95. 6. Guan W-j, Gao Y-h, de la Rosa-Carillo D, et al. Cardiovascular implications in bronchiectasis. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 96–107. 7. Downey DG, Elborn JS. Cardiovascular complications of cystic fibrosis. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 108–117. 8. Bonsignore MR, Gallina S, Drager LF. Cardiovascular consequences of sleep disordered breathing: the role of CPAP treatment. In: Martínez-García MA, Pépin J-L, Cazzola M. Cardiovascular Complications of Respiratory Disorders (ERS Monograph). Sheffield, European Respiratory Society, 2020 pp. 118–142. xii https://doi.org/10.1183/2312508X.10005220